Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese

被引:32
|
作者
Takakubo, F
Kuwano, A
Kondo, I
机构
[1] Department of Hygiene, Ehime University, School of Medicine, Onsen-gun
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
(S)-mephenytoin; poor metabolizer; CYP2C19m1 and CYP2C19m2;
D O I
10.1097/00008571-199606000-00011
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
(S)-Mephenytoin is metabolized by CYP2C19. The purpose of this study was to examine availability of phenotyping of poor metabolizers (PMs) of (S)-mephenytoin by polymerase chain reaction(PCR)/restriction enzyme genotyping of CYP2C19 in a Japanese population. We genotyped 217 unrelated healthy Japanese for functionally defective alleles, CYP2C19m1 and CYP2C19m2. The frequencies of the wild type (W-m1) and CYP2C19m1 were 0.726 and 0.274, and the wild type(W-m2) and CYP2C19m2 were 0.892 and 0.108 respectively, Although the observed numbers of three genotypes were very similar to those estimated according to the Hardy-Weinberg equilibrium for each defect, CYP2C19m2 was not detected in m2 homozygotes, and CYP2C19m1 was not detected in m2 homozygotes. Two defects were inherited separately in four families indicating CYP2C19m1 and m2 segregate independently at the same gene locus, Based on these data, we calculated the haplotype frequencies of W-m1-W-m2, CYP2C19m1-W-m2 and W-m1-CYP2C19m2 to be 0.618, 0.274 and 0.108 respectively, frequencies of homozygotes for CYP2C19m1 and CYP2C19m2 and compound heterozygotes associated with the PM phenotype, were calculated to be 7.5, 1.2 and 5.9% respectively, In total, 14.6% of Japanese are estimated to be PMs, No significant difference was observed between the frequencies of PMs calculated from our results and that identified by urinary S/R ratio (18%) (p>0.05, chi 2=0.545, f(d)=1). Our data indicate that Japanese PMs of (S)-mephenytoin could be identified by PCR-based genotyping of CYP2C19.
引用
收藏
页码:265 / 267
页数:3
相关论文
共 50 条
  • [41] Clinical Impact of the CYP2C19 Gene on Diazepam for the Management of Alcohol Withdrawal Syndrome
    Ho, Teresa T. T.
    Noble, Melissa
    Tran, Bao Anh
    Sunjic, Katlynd
    Gupta, Sheeba Varghese
    Turgeon, Jacques
    Crutchley, Rustin D. D.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
  • [42] Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
    Kagami, T.
    Sahara, S.
    Ichikawa, H.
    Uotani, T.
    Yamade, M.
    Sugimoto, M.
    Hamaya, Y.
    Iwaizumi, M.
    Osawa, S.
    Sugimoto, K.
    Miyajima, H.
    Furuta, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (10) : 1048 - 1059
  • [43] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers
    Shao, H.
    Ren, X. M.
    Liu, N. F.
    Chen, G. M.
    Li, W. L.
    Zhai, Z. H.
    Wang, D. W.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (03) : 351 - 360
  • [44] Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites
    Lee, Hye-In
    Byeon, Ji-Young
    Kim, Young-Hoon
    Lee, Choong-Min
    Choi, Chang-Ik
    Jang, Choon-Gon
    Bae, Jung-Woo
    Lee, Yun Jeong
    Lee, Seok-Yong
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (11) : 1417 - 1426
  • [45] SCREENING FOR CYP2C19*2, *3 AND *4 GENE VARIANTS IN A ROMANIAN POPULATION STUDY GROUP
    Buzoianu, Anca D.
    Trifa, Adrian P.
    Popp, Radu A.
    Militaru, Mariela S.
    Militaru, Claudia F.
    Bocsan, Corina I.
    Farcas, Marius F.
    Pop, Ioan V.
    FARMACIA, 2010, 58 (06) : 806 - 817
  • [46] Influence of the Genetic Polymorphisms in the 5′ Flanking and Exonic Regions of CYP2C19 on Proguanil Oxidation
    Satyanarayana, Chakradhara Rao Uppugunduri
    Devendran, Anichavezhi
    Jayaraman, Muthukumaran
    Mannu, Jayakanthan
    Mathur, Premendu P.
    Gopal, Shewade Deepak
    Rajagopal, Krishnamoorthy
    Chandrasekaran, Adithan
    DRUG METABOLISM AND PHARMACOKINETICS, 2009, 24 (06) : 537 - 548
  • [47] CYP2C19 drug-drug and drug-gene interactions in ED patients
    Flaten, Hanna K.
    Kim, Howard S.
    Campbell, Jenny
    Hamilton, Lisa
    Monte, Andrew A.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2016, 34 (02) : 245 - 249
  • [48] Effect on emergence from anesthesia following induction with diazepam and its association with CYP2C9, CYP2C19 and CYP3A4 gene polymorphisms
    Mittal, Tulika
    Badhe, Vk
    Badhe, Divekar
    Ahluwa, Pallavi
    Mittal, Balraj
    Mittal, Rama
    ANAESTHESIA PAIN & INTENSIVE CARE, 2024, 28 (01) : 126 - 138
  • [49] Evaluation of predictive CYP2C19 genotyping assays relative to measured phenotype in a South African cohort
    Dodgen, Tyren M.
    Droegemoeller, Britt I.
    Wright, Galen E. B.
    Warnich, Louise
    Steffens, Francois E.
    Cromarty, A. Duncan
    Alessandrini, Marco
    Pepper, Michael S.
    PHARMACOGENOMICS, 2015, 16 (12) : 1343 - 1354
  • [50] Individualized Therapy for Gastroesophageal Reflux Disease Potential Impact of Pharmacogenetic Testing based on CYP2C19
    Furuta, Takahisa
    Sugimoto, Mitsushige
    Shirai, Naohito
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (04) : 223 - 234